Bacillus Calmette-Guerin initiates intracellular signaling in a transitional carcinoma cell line by crosslinking α5β1 integrin

被引:21
作者
Chen, FH
Zhang, GJ
Iwamoto, Y
See, WA
机构
[1] Med Coll Wisconsin, Dept Urol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA
关键词
bladder; bladder neoplasms; Mycobacterium bovis; interleukin-6; integrin alpha5beta1;
D O I
10.1097/01.ju.0000067623.43110.4c
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The adherence of bacillus Calmette-Guerin (BCG) to the surface of transitional carcinoma tumor cells initiates nuclear factor (NF)-kappaB signal transduction pathways that modulate the expression of proteins important in the antitumor response to BCG. We tested the hypothesis that BCG initiates NF-kappaB signaling as a consequence of cross-linking alpha5beta1 integrin receptors present on the tumor cell surface. Materials and Methods: The effect of alpha5beta1 antibody mediated cross-linking on interleukin (IL)-6 mRNA expression, IL-6 promoter activation and activation of a specific NF-kappaB reporter construct was determined. A series of reporter constructs containing nonfunctional mutations in the AP-1, NF-IL-6 and NF-kappaB sites were used to determine the relative importance of these response elements in alpha6beta1 cross-linking mediated activation of the IL-6 promoter. A final series of experiments assessed the role of alpha5beta1 receptor occupancy by fibronectin (FN) in initiating antibody or BCG mediated signaling. Results: Antialpha5 and antibeta1 mediated cross-linking of alpha5beta1 integrin initiated NF-kappaB signaling, IL-6 promoter activation and IL-6 mRNA expression. Deletion mutants demonstrated that alpha5beta1 cross-link initiated, IL-6 promoter transactivation required intact NF-kappaB and AP-1 response elements. Receptor occupancy by FN was required for BCG but not for antibody initiated signaling. Conclusions: Cross-linking the alpha5beta1 receptor present on the surface of human transitional carcinoma cells lines initiates signal transduction in a manner identical to that observed for BCG. We propose a model in which multiple FN binding sites present on BCG interact with alpha5beta1 receptor bound FN molecules to cross-link alpha5beta1 receptors and initiate intracellular signaling.
引用
收藏
页码:605 / 610
页数:6
相关论文
共 10 条
[1]  
ASLANZADEH J, 1989, J GEN MICROBIOL, V135, P2735
[2]   Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmette-Guerin through nuclear factor-κB and AP-1 via an immediate early pathway [J].
Chen, FH ;
Crist, SA ;
Zhang, GJ ;
Iwamoto, Y ;
See, WA .
JOURNAL OF UROLOGY, 2002, 168 (02) :786-797
[3]   CYTOKINE PRODUCTION BY THE HUMAN BLADDER-CARCINOMA CELL-LINE T24 IN THE PRESENCE OF BACILLUS-CALMETTE-GUERIN (BCG) [J].
DEREIJKE, TM ;
VOS, PCN ;
DEBOER, EC ;
BEVERS, RFM ;
KEIZER, WHD ;
KURTH, KH ;
SCHAMHART, DHJ .
UROLOGICAL RESEARCH, 1993, 21 (05) :349-352
[4]   INTERLEUKIN-6 PRODUCTION BY BLADDER-TUMORS IS UP-REGULATED BY BCG IMMUNOTHERAPY [J].
ESUVARANATHAN, K ;
ALEXANDROFF, AB ;
MCINTYRE, M ;
JACKSON, AM ;
PRESCOTT, S ;
CHISHOLM, GD ;
JAMES, K .
JOURNAL OF UROLOGY, 1995, 154 (02) :572-575
[5]   Integrins: a role as cell signalling molecules [J].
Jones, JL ;
Walker, RA .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1999, 52 (04) :208-213
[6]   FIBRONECTIN-MEDIATED CALMETTE-GUERIN BACILLUS ATTACHMENT TO MURINE BLADDER MUCOSA - REQUIREMENT FOR THE EXPRESSION OF AN ANTITUMOR RESPONSE [J].
KAVOUSSI, LR ;
BROWN, EJ ;
RITCHEY, JK ;
RATLIFF, TL .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (01) :62-67
[7]  
Malkowicz S B, 2000, Semin Urol Oncol, V18, P280
[8]  
RATLIFF TL, 1987, CANCER RES, V47, P1762
[9]   NEW PERSPECTIVES IN CELL-ADHESION - RGD AND INTEGRINS [J].
RUOSLAHTI, E ;
PIERSCHBACHER, MD .
SCIENCE, 1987, 238 (4826) :491-497
[10]   Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the α5β1 fibronectin receptor [J].
Zhang, GJ ;
Crist, SA ;
McKerrow, AK ;
Xu, Y ;
Ladehoff, DC ;
See, WA .
JOURNAL OF UROLOGY, 2000, 163 (05) :1553-1559